Literature DB >> 22534357

Irreversible electroporation in eradication of rabbit VX2 liver tumor.

Edward W Lee1, Daphne Wong, Bashir A Tafti, Veronica Prieto, Mariam Totonchy, John Hilton, Sarah Dry, Sona Cho, Christopher T Loh, Stephen T Kee.   

Abstract

PURPOSE: To show the effectiveness and safety of irreversible electroporation (IRE) in treating large tumor models.
MATERIALS AND METHODS: VX2 liver tumor implantation was performed in 35 New Zealand White Rabbits. The rabbits were divided into three groups 1 week after implantation. The control group included 15 rabbits; the remaining 20 rabbits were divided into two IRE treatment groups. For the treatment groups, 10 rabbits underwent ablation with a single IRE application (IRE-S group), and 10 rabbits underwent ablation with multiple IRE applications (IRE-M group). Treatments and outcomes were analyzed using ultrasound, contrast-enhanced computed tomography (CT), and immunohistologic staining (hematoxylin and eosin [H&E], P-53, Ki-67, CD30, and vascular endothelial growth factor receptor [VEGFR] staining, and terminal deoxynucleotidyl-transferase-mediated 2'-deoxyuridine 5'-triphosphate [dUTP]-biotin nick-end labeling [TUNEL] assay).
RESULTS: Multiple IRE ablations consistently produced complete cell death in all the animals in the IRE-M group (n = 10, IRE ablation time 2.45 minutes ± 0.3). The results were validated with ultrasound, CT, H&E, Ki-67, P53, and TUNEL assay. A high level of CD30-positive cells were identified in the IRE groups. A sharply demarcated ablation zone with no damage to surrounding vital structures was observed in all IRE-treated tissues. No complications during or after ablation were observed in any of the animals.
CONCLUSIONS: The effects of IRE were shown in a large tumor model with single and multiple IRE ablations (IRE-S and IRE-M treatment groups); complete ablation of the tumor was seen in the IRE-M group. These findings successfully show the beneficial effects and safety of IRE in the treatment of tumors and validate its potential as a clinically translatable treatment.
Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22534357     DOI: 10.1016/j.jvir.2012.02.017

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  16 in total

Review 1.  Update on treatment of liver metastases: focus on ablation therapies.

Authors:  Jeffrey Meyer; Seth Toomay
Journal:  Curr Oncol Rep       Date:  2015-01       Impact factor: 5.075

Review 2.  Electroporation and Immunotherapy-Unleashing the Abscopal Effect.

Authors:  Tobias Freyberg Justesen; Adile Orhan; Hans Raskov; Christian Nolsoe; Ismail Gögenur
Journal:  Cancers (Basel)       Date:  2022-06-10       Impact factor: 6.575

3.  Multimodality imaging to assess immediate response to irreversible electroporation in a rat liver tumor model.

Authors:  Yue Zhang; Sarah B White; Jodi R Nicolai; Zhuoli Zhang; Derek L West; Dong-Hyun Kim; A Lee Goodwin; Frank H Miller; Reed A Omary; Andrew C Larson
Journal:  Radiology       Date:  2014-02-18       Impact factor: 11.105

Review 4.  Development, growth, propagation, and angiographic utilization of the rabbit VX2 model of liver cancer: a pictorial primer and "how to" guide.

Authors:  Ahmad Parvinian; Leigh C Casadaban; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2014 Jul-Aug       Impact factor: 2.630

5.  Irreversible Electroporation of Malignant Hepatic Tumors--Alterations in Venous Structures at Subacute Follow-Up and Evolution at Mid-Term Follow-Up.

Authors:  Marco Dollinger; René Müller-Wille; Florian Zeman; Michael Haimerl; Christoph Niessen; Lukas P Beyer; Sven A Lang; Andreas Teufel; Christian Stroszczynski; Philipp Wiggermann
Journal:  PLoS One       Date:  2015-08-13       Impact factor: 3.240

6.  Combination of interventional adenovirus-p53 introduction and ultrasonic irradiation in the treatment of liver cancer.

Authors:  Jin-Song Qi; Wen-Hui Wang; Fen-Qiang Li
Journal:  Oncol Lett       Date:  2014-12-18       Impact factor: 2.967

7.  Electric Ablation with Irreversible Electroporation (IRE) in Vital Hepatic Structures and Follow-up Investigation.

Authors:  Xinhua Chen; Zhigang Ren; Tongyin Zhu; Xiongxin Zhang; Zhiyi Peng; Haiyang Xie; Lin Zhou; Shengyong Yin; Junhui Sun; Shusen Zheng
Journal:  Sci Rep       Date:  2015-11-09       Impact factor: 4.379

8.  Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial).

Authors:  Hester J Scheffer; Laurien G P H Vroomen; Karin Nielsen; Aukje A J M van Tilborg; Emile F I Comans; Cornelis van Kuijk; Bram B van der Meijs; Janneke van den Bergh; Petrousjka M P van den Tol; Martijn R Meijerink
Journal:  BMC Cancer       Date:  2015-10-24       Impact factor: 4.430

9.  Irreversible electroporation of the liver: is there a safe limit to the ablation volume?

Authors:  P Sánchez-Velázquez; Q Castellví; A Villanueva; R Quesada; C Pañella; M Cáceres; D Dorcaratto; A Andaluz; X Moll; M Trujillo; J M Burdío; E Berjano; L Grande; A Ivorra; F Burdío
Journal:  Sci Rep       Date:  2016-04-01       Impact factor: 4.379

10.  Magnetic Resonance Imaging Findings After Percutaneous Irreversible Electroporation of Liver Metastases: A Systematic Longitudinal Study.

Authors:  Alexandra Barabasch; Martina Distelmaier; Philipp Heil; Nils Andreas Krämer; Christiane K Kuhl; Philipp Bruners
Journal:  Invest Radiol       Date:  2017-01       Impact factor: 6.016

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.